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National guidelines recommend cascade genetic testing (CGT) for blood relatives 
after a cancer predisposition gene mutation is identified in an individual. Despite 
recommendations for CGT, only 30-60% of first-degree relatives (FDRs) complete CGT. 
The proportion of untested relatives who are planning to have CGT is unknown. We used the 
Transtheoretical Model to assess the readiness (stage of change) for CGT among living, 
untested FDRs at-risk for a hereditary predisposition to cancer.   
An anonymous, online survey was open to U.S. adults with an autosomal dominant, 
adult-onset, hereditary predisposition to cancer. Participants reported demographic 
information, their genetic testing information, and information on FDRs (the number of each 
relative, vital status, uptake of CGT, and readiness for CGT among those alive and untested). 
Data were analyzed using descriptive statistics, non-parametric McNemar, Friedman, 
Wilcoxon Signed Rank, Kruskal-Wallis, and Mann-Whitney tests.  A two-sided p-value of 
0.05 was considered statistically significant. 
 Responses were analyzed from 150 predominantly female (88.0%), white (93.3%) 
and non-Hispanic (92.7%) adults. Commonly reported gene were CHEK2 (28.7%), 
BRCA1/2 (23.3%), the Lynch syndrome genes (16.0%), and the SDHB and SDHC genes 
(13.3%), all associated with cancer and tumor risks for men and women.  Participants 
reported 825 FDRs, of which, 70.3% were aware of the mutation, and 30.5% had completed 
CGT. Rates of CGT were higher in siblings than parents or children (p<0.001). Rates of CGT 
varied by sex, whereby mothers and sisters had higher rates of CGT than fathers and brothers 
(p<0.001 and p=0.002, respectively). Of living, untested FDRs, 79.4% were in the 
precontemplation stage and there was no significant difference in readiness by relative’s 
relationship to the participant (p=0.646) or by relative’s sex (p=0.892).  
The rates of awareness and CGT among FDRs in this study are consistent with prior 
studies of CGT. Most untested relatives were in the precontemplation stage and not planning 
to have CGT in the next six months. Future programs to support CGT may consider 
interventions grounded in stage-matched processes of change and should evaluate the 
decision-making processes of relatives to better understand and support the information and 
counseling needs of untested relatives. 
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 1 
BACKGROUND 
Inherited Predisposition to Cancer 
Approximately five to ten percent of all cancers are due to a germline mutation 
(pathogenic or likely pathogenic variant) in a cancer predisposition syndrome gene, often 
referred to as hereditary cancer (National Cancer Institute, 2017). Hereditary cancer 
syndromes are characterized by significantly increased risks over one’s lifetime to develop 
cancers or tumors, increased risk to develop multiple primary cancers, a family history of 
early-onset cancers, patterns of specific cancer types occurring within the family, and cancer 
occurring in multiple generations of a family (American Cancer Society medical and editorial 
content team, 2017). When an individual has a personal or family history with the features of 
a hereditary cancer syndrome, evaluation may be performed with a genetics professional 
(genetic counselor, genetics nurse, or geneticist) and through germline genetic testing. 
Hereditary cancer syndromes can be categorized by their penetrance, prevalence in 
the general population, adult or childhood onset, and inheritance pattern.  Penetrance refers to 
the proportion of individuals with a genetic mutation who develop the features, or phenotype, 
of the genetic syndrome or condition (Griffiths, 2000).  There are three categories of 
hereditary cancer gene penetrance: high, moderate, and low penetrance (Economopoulou, 
Dimitriadis, & Psyrri, 2015).  Hereditary cancer syndromes caused by high penetrance gene 
mutations are the most clinically relevant, and are associated with a greater than 5 times 
increased relative risk to develop cancer, as compared to moderate penetrant (1.5 to 5 times 
increased relative risk) and low penetrant (1.5 times increased relative risk) hereditary cancer 
gene mutations (Economopoulou et al., 2015).  Typically, high penetrant hereditary cancer 
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gene mutations occur at low frequencies in the general population, while moderate and low 
penetrant mutations are more prevalent (Foulkes, 2008).   
There are two well-studied conditions in the field of clinical cancer genetics 
characterized by their high-penetrance, relatively high population prevalence, adult-onset 
cancer risks and autosomal-dominant inheritance: Hereditary Breast and Ovarian Cancer 
syndrome (HBOC) and Lynch syndrome (also known as Hereditary Nonpolyposis Colorectal 
Cancer or HNPCC). These two conditions are included in the CDC’s Tier 1 Genomics 
Applications due to their significant potential for positive impact on public health if 
identified and if prevention and early detection interventions are initiated (O. o. P. H. G. 
Centers for Disease Control and Prevention, 2014).   
HBOC is caused by inherited mutations in the BRCA1 and BRCA2 genes, which is 
estimated to occur in 1:400 – 1:500 individuals in the general population, and 1:40 
individuals in the Ashkenazi Jewish population (Petrucelli N, 1998).  Individuals with a 
mutation in BRCA1 or BRCA2 are estimated to have significantly increased risks of adult-
onset female breast cancer (38-87% lifetime risk), ovarian cancer (17-39% lifetime risk), 
male breast cancer (1.2-8.9% lifetime risk), prostate cancer (8.6-20% lifetime risk), as well as 
increased risks for pancreatic cancer and melanoma (Petrucelli N, 1998).  HBOC is inherited 
in an autosomal dominant pattern, indicating that men and women can inherit a BRCA1 or 
BRCA2 mutation, it does not “skip” generations, and that each child has a50% chance to 
inherit the mutation (Petrucelli N, 1998).   
Lynch syndrome is caused by a mutation in MLH1, MSH2/EPCAM, MSH6, or PMS2, 
which is estimated to occur in 1:440 individuals in the general population (Kohlmann, 2004).  
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Individuals with a Lynch syndrome gene mutation have significantly increased risks to 
develop adult-onset colorectal cancer (52-82% lifetime risk), endometrial/uterine cancer (25-
60% lifetime risk), ovarian cancer (4-12% lifetime risk), gastric/stomach cancer (6-13% 
lifetime risk), and other cancers; however cancer risks vary depending on which gene is 
involved (Kohlmann, 2004).  Lynch syndrome is also inherited in an autosomal dominant 
fashion (Kohlmann, 2004). 
Criteria for identifying individuals who may have a higher likelihood of having 
HBOC or Lynch syndrome, and who are recommended to have genetic testing are outlined 
by the National Comprehensive Cancer Network (NCCN) guidelines (National 
Comprehensive Cancer Network, 2018a, 2018b). Genetic testing for hereditary cancer 
predisposition genes in the United States has changed over the past several years due to the 
impact of a variety of legal and cultural factors.  Influences include the increased use of next-
generation sequencing technology to decrease the time and cost of genetic testing, the 
Supreme Court ruling in the Association for Molecular Pathology vs. Myriad prohibiting 
gene patents, the public announcement by Angelina Jolie of her HBOC diagnosis and 
subsequent risk-reducing bilateral mastectomy, and the increasing calls for precision 
medicine in health care (Borzekowski, Guan, Smith, Erby, & Roter, 2014; Hooker et al., 
2017). In response to several of these factors, genetic testing for hereditary cancer syndromes 
increasingly relies upon the use of multi-gene panels, which evaluate both high and moderate 
penetrant genes associated with a variety of cancer predisposition syndromes in a single 
genetic test. As the use of multi-gene panel genetic testing increased, a greater number of 
individuals have been identified to have moderate-penetrant cancer gene mutations.  
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Examples of moderate penetrant cancer genes frequently detected on multi-gene panel 
genetic testing include mutations in ATM and CHEK2. 
In the past, genetic testing for ATM was primarily performed to evaluate for the rare, 
child-onset, autosomal recessive (homozygous ATM gene mutations) condition: ataxia-
telangiectasia (Gatti, 1999). Individuals with a single, heterozygous ATM mutation are 
estimated to have a 4-fold increased risk to develop breast cancer, consistent with a moderate 
penetrant cancer predisposition gene (Gatti, 1999). An estimated 1-2% of the general 
population have a heterozygous ATM mutation (Jerzak, Mancuso, & Eisen, 2018). Germline 
variants in CHEK2 are also classified as moderate-penetrant cancer genes with associated 
breast cancer risks estimated to be 2-3 times increased over general population risks, with a 
prevalence of the common 1100delC CHEK2 mutation of approximately 1% of the general 
population (Apostolou & Papasotiriou, 2017; Foulkes, 2008). Although mutations in these 
moderate-penetrant cancer genes are both inherited in an autosomal dominant fashion, and 
are more common than mutations in the high-penetrant HBOC and Lynch syndrome genes, 
the optimal breast cancer screening and risk-reducing strategy for these genes has not been 
identified. While management recommendations for these genes are available from the 
NCCN, these recommendations have been based on general consensus and extending prior 
breast cancer risk-based screening approaches, and may evolve over time as more studies are 
performed (National Comprehensive Cancer Network, 2018a). 
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Implications of Identifying a Hereditary Predisposition to Cancer 
When an individual undergoes evaluation for a hereditary predisposition to cancer, 
genetic testing is offered if NCCN genetic testing criteria are met and if the individual is an 
informative candidate for testing within their family.  Informed consent for genetic testing for 
hereditary predisposition to cancer include discussion of the purpose and indication for the 
genetic testing, potential outcomes, benefits and limitations of the information obtained from 
the test, and considerations regarding patient privacy and genetic discrimination protections 
(Riley et al., 2012).  Concerns for discrimination based on the results of genetic testing is a 
relevant concern for many individuals, however the Genetic Nondiscrimination Act of 2008 
prohibited genetic discrimination in employment and health insurance and the Affordable 
Care Act of 2010 protection for individuals with “pre-existing conditions” have increased 
protections against discrimination (Allain, Friedman, & Senter, 2012; Brooks, Hoverman, & 
Colla, 2017).  While protections have increased over time, there are limitations to existing 
laws and not all health insurance policies and employers fall under the protections of GINA, 
and discrimination continues to be permitted among life insurance, long-term care, and 
disability insurance policies (Allain et al., 2012). 
Cost is also a relevant consideration during the informed consent process prior to 
performing genetic testing.  In the United States, most private health insurance payers 
recognize the NCCN guidelines as the criteria for hereditary cancer genetic testing approval.  
Medicare has similar guidelines for coverage of genetic testing, however requires that the 
individual undergoing genetic testing have a personal history or diagnosis of a relevant 
cancer. Patients who are uninsured, underinsured, or covered by a policy with a genetic 
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testing exclusion may qualify for no-cost or reduced cost genetic testing through financial 
assistance programs of the genetic testing laboratories (Hinchcliff, Bednar, Lu, & Rauh-Hain, 
2019).  The out-of-pocket costs for hereditary cancer genetic testing have decreased from the 
$4000 list price of testing of five to ten years ago, now to self-pay prices of $250 or less in 
2019.  
There are significant implications for an individual when genetic testing identifies a 
hereditary cancer gene mutation. A hereditary cancer gene mutation indicates that the tested 
individual has inherited increased risks to develop specific cancers, as informed by the gene 
and the mutation identified. Guided by the increased cancer risks, the individual qualifies for 
high-risk cancer screenings, and consider risk-reduction and cancer prevention procedures.  
For example, the identification of a BRCA1 or BRCA2 mutation in a woman would indicate 
significantly increased lifetime risks to develop breast and ovarian cancer.  The NCCN 
management recommendations for a woman with HBOC include: high-risk breast cancer 
screening including annual mammogram with breast MRI beginning as early as age 25, 
ovarian cancer risk-reduction through bilateral salpingo-oophorectomy (removal of the 
ovaries and fallopian tubes) upon completion of childbearing or by age 35-45, and options 
for chemoprevention including oral contraceptive pills and/or selective estrogen receptor 
modulators (National Comprehensive Cancer Network, 2018a).  Likewise, if an individual is 
found to have a Lynch syndrome mutation, NCCN management recommendations include 
frequent colonoscopy screening every 1-2 years beginning as early as age 25, and screening 
for endometrial and ovarian cancer with consideration of risk-reducing hysterectomy 
(National Comprehensive Cancer Network, 2018b).  Even moderate penetrant genes, such as 
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ATM or CHEK2 have NCCN recommended high-risk breast cancer screening (National 
Comprehensive Cancer Network, 2018a). 
If the individual undergoing genetic testing has a diagnosis of cancer for which they 
are undergoing treatment, the results may have direct implications on cancer treatment.  For 
women with ovarian cancer associated with an inherited BRCA1 or BRCA2 mutation, 
treatment with a PARP inhibitor may be recommended (Buchtel et al., 2018). Other cancer 
types are also testing the use of PARP inhibitor therapy, primarily in breast, pancreatic, and 
prostate cancers (Dalia, Christopher, Jagdeep Singh, & Vikaash, 2018). For individuals with 
colorectal cancer or advanced-stage endometrial cancer with a Lynch syndrome gene 
mutation, immunotherapy may be indicated (Longoria & Eskander, 2015). Targeted therapy 
is a growing field of research and drug development, which may provide new treatment and 
prevention options to patients and families with hereditary cancer predisposition syndromes 
in the coming years. 
Additionally, the identification of a hereditary cancer gene mutation indicates that the 
mutation was, in most cases, inherited and that the individual may pass the mutation on to 
offspring. Results have direct implications for first-degree blood-relatives and other, more 
distant relatives of the tested individual. 
 
Cascade Genetic Testing 
Cascade genetic testing is the process of performing genetic testing for blood relatives 
of individuals with a hereditary cancer gene mutation, whereby relatives are tested for the 
specific gene mutation identified in their family member (American College of Obstetricians 
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and Gynecologists, 2018; Caswell-Jin et al., 2018). Cascade genetic testing is a systematic 
approach of initiating mutation-specific genetic testing starting with first-degree relatives, so 
that their genetic testing status can then inform second- and third-degree relatives of their the 
risk to inherit the mutation.  Cascade genetic testing can identify relatives who have inherited 
the mutation and the associated cancer risks, and identify relatives who have not inherited the 
mutation (also known as “true negative”) who then have cancer risks most comparable to 
individuals in the general population.  
Since mutation status can have a significant impact on the initiation and frequency of 
cancer screening for at-risk relatives, cascade genetic testing is recommended by the NCCN 
guidelines, the American College of Obstetricians and Gynecologists, the Evaluation of 
Genomic Applications in Practice and Prevention group, and the Society of Gynecologic 
Oncology (American College of Obstetricians and Gynecologists, 2018; EGAPP Working 
Group, 2009; National Comprehensive Cancer Network, 2018a, 2018b).  Although cascade 
genetic testing is recommended by a variety of national organizations and can provide 
important information for relatives, the uptake of testing among at-risk relatives is not robust.  
A systematic review of 30 published studies evaluated the communication of genetic 
testing results and the uptake of cascade genetic testing in families with HBOC and Lynch 
syndrome (Menko et al., 2018).  Generally, families share and communicate the genetic 
testing results with relatives at high rates, with most studies reporting that 75% to 90% of 
relatives were aware of the genetic testing results in the family (Menko et al., 2018).  
However, the uptake of cascade genetic testing among at-risk relatives is lower, with most 
studies reporting cascade genetic testing rates of 20% to 50% (Menko et al., 2018). Cascade 
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genetic testing rates in families with moderate-penetrant hereditary cancer predispositions 
have not been reported.  
Researchers and clinicians have been evaluating the clinical processes for offering 
and coordinating genetic testing, and implementing various interventions in an attempt to 
increase the uptake of cascade genetic testing.  There are three general processes that are 
considered in the study of cascade genetic testing, including family communication, access to 
genetic testing services, and the role of barriers, facilitators, and determinants of individual 
behavior.  
The first cascade genetic testing consideration is the process of communicating risk 
information and cascade testing recommendations within the family.  An at-risk relative may 
not know that they are at risk for an inherited cancer predisposition syndrome without 
receiving this information from either a relative found to have a mutation or from a health 
care provider able to identify family histories with characteristics of hereditary cancer 
syndromes. In the setting whereby a hereditary cancer mutation is identified in a relative, the 
typical clinical practice after a mutation is found is for a healthcare provider to discuss the 
inheritance pattern of the mutation and the implications for relatives during a post-test 
genetic counseling consultation.  Genetic counselors and other health care providers 
encourage the patient or “proband” with the gene mutation to inform their relatives of the 
risk to have the mutation, and the recommendation for relatives to pursue cascade genetic 
testing. Often, a “family letter” is shared with the patient to facilitate transmission of the 
information to relatives, however this approach does not guarantee success of information 
sharing within families and may impose a burden upon the patient (Dheensa, Lucassen, & 
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Fenwick, 2017). Given the concern that family letters may not reach at-risk relatives, direct 
contact of relatives by health care providers has been evaluated. 
Studies have assessed the awareness and cascade genetic testing-related effects of 
direct contact of blood relatives by a health care provider with the consent of the patient.  The 
results of direct-contact approaches on family communication and uptake of cascade genetic 
testing are mixed, and may not be acceptable in all patient populations (Aktan-Collan et al., 
2007; Forrest, Burke, Bacic, & Amor, 2008; Hodgson et al., 2016; Suthers, Armstrong, 
McCormack, & Trott, 2006).  Ethical considerations regarding communication of genetic 
testing results, especially from the perspective of health care providers have been well 
documented, and include debates over the balance of individual patient autonomy and 
privacy with the physician’s duty to warn relatives of a hereditary disease risk (Offit, 
Groeger, Turner, Wadsworth, & Weiser, 2004). 
Other approaches to increase communication of genetic testing results within families 
have included a randomized study of a six-step communication skills-building program (Daly 
et al., 2001). The outcomes of this intervention found that the communication training did not 
significantly improve the sharing of information within families with hereditary cancer 
syndromes compared to individuals not receiving the intervention, and it did not significantly 
improve the ability of relatives to accurately report the genetic testing result of the relative 
(Daly, Montgomery, Bingler, & Ruth, 2016; Montgomery et al., 2013). A second study to 
improve communication within families assessed the acceptability of a motivational 
interviewing intervention to aid patients in sharing the genetic testing results with relatives. 
While the intervention was acceptable, the communication and cascade genetic testing rates 
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were not reported (de Geus et al., 2016).  A pilot educational intervention to promote risk 
information sharing within families with HBOC found no statistically significant difference 
in communication or cascade genetic testing when comparing the control and intervention 
groups (Kardashian, Fehniger, Creasman, Cheung, & Beattie, 2012). Approaches to 
improving communication within families have had limited impact on outcomes of relatives’ 
awareness of their risk status or uptake of cascade genetic testing. 
The second consideration regarding cascade genetic testing is the process by which 
relatives access genetics services including genetic testing.  Studies have sought to decrease 
the frequently reported financial and geographic barriers to accessing genetic counseling and 
genetic testing for relatives. A genetic testing laboratory studied the uptake of reduced cost 
($50) cascade genetic testing coordinated through an online platform by first-degree relatives 
invited to participate by their mutation-positive family member (Caswell-Jin et al., 2018).  
The study identified that 48% of invited relatives underwent cascade genetic testing through 
the online platform, similar to cascade genetic testing rates reported in clinical genetic testing 
settings (Caswell-Jin et al., 2018).  Other ongoing research studies, like the MAGENTA and 
GENERATE studies, also allow relatives to access no-cost or reduced-cost cascade genetic 
testing through an online platform, however the impact of this cascade genetic testing 
delivery model on the uptake of cascade testing among relatives is yet to be demonstrated 
(U.S. National Library of Medicine, 2016, 2018). 
Prior intervention studies have focused primarily on barriers to cascade genetic 
testing that are external to the individual relative, including the interpersonal communication 
between patients and at-risk relatives, and the interaction between at-risk relatives and the 
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health care system. The mixed or null outcomes of interventions acting upon these external 
barriers to improve cascade genetic suggests that the cascade genetic testing process may be 
more complex, and that additional factors and determinants have not been fully evaluated or 
incorporated into prior intervention studies. The third consideration for cascade genetic 
testing is the role of personal barriers, facilitators, and determinants of testing.  A logic model 
of cascade genetic testing, in Figure 1 includes factors that may impede cascade genetic 
testing in at-risk relatives, based on existing literature.  External factors that serve as barriers 
to cascade genetic testing, in addition to cost or geographic access, include incomplete anti-
discrimination policies, incomplete health insurance coverage of recommended high-risk 
screening and risk-reducing procedures in the U.S.; lack of recommendation for genetic 
testing from healthcare providers, and competing demands on individual’s time (such as 
employment and childcare) (Allain et al., 2012; Anderson et al., 2012; Hamilton et al., 2017; 
Jbilou et al., 2014; Nair et al., 2017; Prince, 2015; Roberts et al., 2018).  Also included in 
Figure 1 are various personal psychosocial determinants identified to influence an 
individual’s decision to pursue genetic testing, such as attitudes about genetic testing, 
perceived risks of testing, and self-efficacy to pursue testing (Sweeny, Ghane, Legg, Huynh, 
& Andrews, 2014).   
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Figure I. Logic Model of the Problem: Lack of Cascade Genetic Testing  
 
 
There are opportunities to apply behavioral science theories to evaluate the 
interaction and impact of these various psychosocial determinants on cascade genetic testing 
processes, and to develop appropriate clinical interventions for this population.  One 
framework that could combine behavioral science theory with cascade genetic testing 
programs and interventions is intervention mapping.  Intervention mapping provides a multi-
step framework for program development, production, implementation and evaluation that is 
grounded in behavioral science theories (Bartholomew Eldredge et al., 2016). Intervention 
mapping has been used sparingly in cancer prevention and control program design, and rarely 
in clinical cancer genetics research, as a 2018 systematic review of cancer-related 
interventions using intervention mapping identified only one published study of intervention 
mapping used in hereditary cancer research (Lamort-Bouché et al., 2018). 
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The Transtheoretical Model 
One behavioral science theory, the Transtheoretical model (TTM), was developed by 
comparative analysis of numerous theories of psychotherapy, health behavior, and 
psychopathology (J.O. Prochaska, Redding, & Evers, 2015).  The TTM has two primary 
components: the Stages of Change, which are the steps of changing a behavior over time, and 
the Processes of Change, which are the ways in which a behavior is changed (J.O. Prochaska 
et al., 2015). The TTM was first applied in populations of adult smokers to evaluate their use 
of processes of change, and progress through the stages of change as they attempted to quit 
smoking. The TTM has since been applied to a variety of other health behaviors, such as 
cancer screening, medication compliance, and alcohol abuse; however, the TTM has not been 
applied to evaluate cascade genetic testing within families (J.O. Prochaska et al., 2015; James 
O. Prochaska & Velicer, 1997). Cascade genetic testing is a behavior that an individual must 
contemplate, make a decision about, then prepare to take action over a period of time, which 
is similar to other behaviors studied using the TTM.  One relevant difference is that most 
health behaviors evaluated using the TTM occur repeatedly over time, while cascade genetic 
testing occurs only once for an individual; therefore, the stages of change after a behavior has 
occurred (maintenance, termination, and relapse) are likely not relevant in cascade genetic 
testing processes. 
The TTM outlines six stages of change, based on the readiness to change or perform a 
health behavior, including: precontemplation, contemplation, preparation, action, 
maintenance, and termination (J.O. Prochaska et al., 2015).  Individuals may move through 
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the stages one by one, but may also relapse to a prior stage. The precontemplation stage is the 
“least ready” to make a behavior change, and is defined as having no intention to take action 
within the next six months (J.O. Prochaska et al., 2015). Contemplation stage is when an 
individual intends or plans to take action and change behavior within the next six months, 
and preparation stage is when an individual intends take action within the next thirty days. 
The action stage represents that the behavior change has occurred, but is a recent change, 
having occurred within the past six months.  The later stages, maintenance and termination, 
represent prolonged behavior change for more than 6 months, and when there is no 
temptation to relapse, respectively. When evaluating the distribution of individuals across the 
stages of change for a variety of health behaviors, generally 40% of individuals are in 
precontemplation stage, 40% are in contemplation stage, and 20% are in preparation stage 
(James O. Prochaska & Velicer, 1997). It is unknown if at-risk relatives will be similarly 
distributed across these stages for the behavior of cascade genetic testing. 
Specific processes of change are associated with each stage of change, and 
application of appropriate processes can help individuals progress toward the action stage of 
change.  For individuals in the precontemplation stage, the associated processes of change 
include consciousness raising, dramatic relief, and environmental re-evaluation (J.O. 
Prochaska et al., 2015).  Consciousness raising is the process of obtaining information to 
increase awareness and understanding of the health problem(s) associated with the behavior 
(J.O. Prochaska et al., 2015; Romain, Horwath, & Bernard, 2018).  Dramatic relief is the use 
of emotions (positive or negative) to motivate behavior change (J.O. Prochaska et al., 2015).  
Environmental re-evaluation is the process of considering the rational and emotional impacts 
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of one’s behavior upon their social and physical environments (J.O. Prochaska et al., 2015; 
Romain et al., 2018).   
Individuals moving between the contemplation and preparation stage may employ the 
self-reevaluation process of change (J.O. Prochaska et al., 2015). Self-reevaluation is the 
process of evaluating the rational and emotional impact of the behavior on one’s self and 
self-image (J.O. Prochaska et al., 2015; Romain et al., 2018).   Finally, individuals in 
preparation moving toward action may employ self-liberation processes (J.O. Prochaska et 
al., 2015).  The self-liberation process of change includes recognition of social norms, belief 
in ability to make a change in behavior, and the ability to commit to take action (J.O. 
Prochaska et al., 2015; Romain et al., 2018).  Throughout the stages of change, the constructs 
of decisional balance and self-efficacy can impact behavior change (J.O. Prochaska et al., 
2015).  Decisional balance can be described as the balance of perceived pros (benefits) and 
cons (risks or limitations) to making a behavior change, whereas self-efficacy describes the 
confidence and perceived ability to make a change (J.O. Prochaska et al., 2015).  
The TTM constructs have been applied sparingly in the field of clinical cancer 
genetics.  One study published in 1997 applied the TTM constructs of stage of change and 
decisional balance to evaluate whether women undergoing mammography screening were 
interested in having a hypothetical genetic test for hereditary breast cancer (Jacobsen, 
Valdimarsdottir, Brown, & Offit, 1997).  The study found that approximately 46% of 
surveyed women were in preparation stage for this hypothetical genetic test, 30% were in 
contemplation stage, and 24% were in precontemplation stage, whereby the decisional 
balance score was a predictor of readiness to pursue genetic testing (Jacobsen et al., 1997).  
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A second study applied only the decisional balance construct of TTM to a population of 
high-risk women with breast cancer to understand why some did not complete a 
recommended genetic counseling appointment (O'Neill, Peters, Vogel, Feingold, & 
Rubinstein, 2006).  Recently, a randomized controlled trial evaluated the impact of a 
psychoeducational intervention on the TTM stage of change (intent) to pursue cancer genetic 
counseling among patients with breast cancer (Kasting et al.).  This study reported that 55% 
of patients were in precontemplation and 39% were in contemplation at baseline, and after 
the intervention, 28% of participants moved toward action stage compared to 7.7% in the 
control group (p=0.01) (Kasting et al.).  To date, no studies have applied the TTM to cascade 
genetic testing among relatives at-risk for a hereditary predisposition to cancer. 
 
Public Health Significance 
Diagnosing and investigating health problems; informing, educating, and empowering 
individuals about health issues; and linking people to personal health services are essential 
public health services that apply to the promotion and delivery of cascade genetic testing 
within families at increased risk for hereditary cancer (Centers for Disease Control and 
Prevention, 2018). Caring for populations with higher than average risk for disease is an 
activity included within the essential public health service of monitoring health status 
(University of Kansas, 2018).   
Additionally, Healthy People 2020 includes two objectives specific to hereditary 
cancer genetic counseling and genetic testing: (G-1) to increase the proportion of women 
with a family history of breast and ovarian cancer who receive genetic counseling, and (G-2) 
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to increase the proportion of individuals with colorectal cancer who receive genetic 
counseling and genetic testing for Lynch syndrome (Office of Disease Prevention and Health 
Promotion, 2017).  The inclusion of cancer genetic counseling and genetic testing objectives 
in this population health program signifies the relevance, importance, and potential impact of 
identifying and appropriately managing individuals with hereditary cancer predispositions.   
Cascade genetic testing is an efficient and cost-effective approach to identifying 
individuals with the highest probability of having a hereditary cancer predisposition, in an era 
of increasing health care costs and over-treatment (Ansari et al., 2012; Lyu et al., 2017; 
Tuffaha et al., 2018). While families with hereditary predispositions to cancer are “rare” in 
the general population, they represent an important high-risk population of individuals where 
specific, effective risk reduction and cancer prevention options are available, warranting the 
attention and efforts of public health agencies. Cascade genetic testing may be one of the 
strongest examples of the how our health care and public health systems could increase 
efforts around “precision prevention,” whereby individual genetic information is used to 
tailor medical care and prevention activities to optimize health outcomes (Yurgelun, 
Chenevix-Trench, & Lippman, 2017). 
 
Hypothesis, Research Question, Specific Aims or Objectives 
The research study aims to address the question: what is the distribution of stage of 
change (readiness) for cascade genetic testing among living, untested, at-risk first-degree 
relatives? The primary objective of the study is to evaluate what proportion of living, at-risk, 
first-degree relatives who have not undergone cascade testing for a hereditary predisposition 
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to cancer are in the TTM’s precontemplation, contemplation, preparation, and action stages 
of change.   
Secondary study objectives are to evaluate what proportion of first-degree relatives 
are aware of the mutation in the family, and have undergone cascade testing.  Additionally, 
we aim to evaluate associations between first-degree relatives’ awareness and cascade testing 
status with their sex, relationship to the participant (parent, sibling, child), gene mutated in 
the family, involvement of a genetics professional in participant’s genetic testing, and 
participant’s demographic factors. 
 
METHODS 
Study Design 
We developed and implemented an anonymous survey of U.S. adults with a 
hereditary predisposition to tumors and cancer to evaluate the cascade genetic testing status 
and readiness for cascade genetic testing among their at-risk first-degree relatives.  The 
survey is a cross-sectional study, measuring the participants’ demographic characteristics, 
and their relatives’ genetic testing status (including vital status, awareness of the mutation in 
the family, and completion of cascade genetic testing), and the readiness to undergo cascade 
genetic testing among living untested relatives at a single point in time.   
Clinical practice and practical considerations informed the design of the study.  
Standard clinical practice following the identification of a hereditary cancer predisposition in 
an adult individual is for the health care provider to encourage the individual to inform their 
relatives of the test results and the recommendation to seek cascade genetic testing.  The 
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individual found to have the hereditary cancer gene mutation serves as a “gatekeeper” of the 
cancer risk information for their family.  Relatives in supportive families with open 
communication behaviors often share health information openly, including updates on their 
genetic counseling and genetic testing status.  An individual found to have a hereditary 
cancer gene mutation might be able to reliably report on the known or suspected genetic 
testing status of relatives with whom they share communication, however this may not 
always occur and depends largely on the communication preferences and interpersonal 
dynamics within a family. 
An alternative approach to the study would be to request responses directly from at-
risk family members, which would need to include those who may not be aware of the 
mutation in their family, and those who are resistant to, or have declined genetic testing.  
Direct contact of these relatives for research purposes has significant ethical implications, 
and from a recruitment perspective, these relatives may be less likely to interact with a 
voluntary research survey about a topic in which they are disinterested, have negative 
feelings, or may perceived as intrusive.  Therefore, to respect family communication 
preferences and to improve the recruitment for the study, we initiated contact with 
individuals with a hereditary cancer gene mutation and asked that individual to report on 
behalf of other family members.  
To respect participant time and effort, the survey was designed to be simple, quick to 
complete, and collect only the minimum information necessary to complete study objectives.  
This study introduced minimal risk to patient safety since it was anonymous and collected no 
personally identifiable health information. The UTHSC Committee for Protection of Human 
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Subjects considered the study exempt, and a waiver of informed consent was obtained 
(protocol number HSC-SPH-180397, See Appendix A for the exempt status approval letter).   
 
Study Population 
Since this was an exploratory and descriptive study, no minimum number of 
participants were required, and no specific outcomes were required or anticipated. 
Participant eligibility/inclusion criteria included: 
• Men and women who are ≥18 years of age, residing in the United States, who are able 
to complete a questionnaire in English, and 
• Have at least one known blood relative, and 
• Have received a “positive” genetic test result, indicating a “deleterious/pathogenic” or 
“suspected deleterious/pathogenic” mutation in one autosomal dominant, adult-onset 
cancer/tumor predisposition genes currently available for clinical genetic testing   
Participant exclusion criteria included: 
• Individuals under the age of 18 at the time of the study, and/or 
• Individuals who are unable to read and complete a questionnaire in English, and/or 
• Individuals who have not undergone genetic testing for a cancer/tumor predisposition 
syndrome, and/or 
• Individuals who have received a “negative” genetic test result, or a “variant of 
uncertain significance” genetic test, without a “positive” result, and/or 
• Individuals who have no knowledge of their blood relative(s) 
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Study Recruitment  
The survey was open to participants for six months (August 1, 2018 through March 1, 
2019). Study recruitment occurred online, and the study was promoted by a Twitter account 
(@CascadeStudy) and by various hereditary cancer patient support and advocacy groups 
such as FORCE (Facing Our Risk of Cancer Empowered), Young Previvors, the Pheo Para 
Project, and others.  Each group or organization who agreed to share the study information 
distributed the survey link and a brief description of the study via the online platform of their 
choice, including but not limited to: e-newsletter, discussion forum, or social media 
(Facebook, Twitter, etc.).  Recruitment materials used for social media distribution are 
available in Appendix B. 
At the completion of the survey, participants could provide their email address to 
enter into a raffle for a $25 gift card.  The personal email address was not tied to the survey 
responses and was not included in data analysis.  The raffle occurred two weeks following 
the close of the survey.  An email was sent to notify the winner to confirm that their email 
address was functional and to send an electronic Amazon gift card.  If the raffle winner’s 
email address was invalid or no response was received after 2 weeks, a new winner was 
selected and notified. 
 
Study Procedures 
The online survey was created and implemented using UTHealth’s Qualtrics 
software. A participant was expected to be able to complete the survey in less than 60 
 23 
minutes; however, time to complete the survey could vary by the size of the participant’s 
family and the extent that the participant preferred to collect information from relatives.  
Collection of information from relatives by the participant was not a requirement of the 
study; however, some participants may have elected to do so.  The median time to complete 
the survey was 7.8 minutes. 
Qualtrics validation tools were implemented for relevant questions (ex: age numbers 
must range from 18-120), and eligibility questions were required to be answered before 
proceeding to family member questions.  Participants who were ineligible for the study based 
on the response to a question were redirected to a thank-you statement, and exited the survey.  
Questions not directly tied to eligibility determination could be skipped or unanswered. 
The following data was collected by the survey: demographic factors of the 
participant including: age, sex, U.S. state of residence, race/ethnicity, and personal history of 
cancer (yes/no question), genetic testing questions (to assess prior testing result, gene 
involved, year testing was completed, and if testing was coordinated by a genetics 
professional or non-genetics professional).  Participants were asked about first-degree 
relatives, including: number, vital status, their awareness of the genetic testing results, their 
uptake of cascade testing, and if no cascade testing and the relative is alive: their stage of 
change. The survey also collected information on second and third degree relatives’ 
including: suspected or confirmed inheritance (maternal or paternal), number of each 
relationship type (aunt, uncle, etc.), number aware of the results, and number who have had 
cascade testing. A question was included to attempt to evaluate what percent of living, 
untested second- and third-degree relatives were in each stage of change, however the 
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question was difficult to interpret without additional information about family structure. 
Ultimately, the results of second and third degree relatives’ awareness and cascade testing 
status were not included in analysis due to the complexity of interpreting the data without 
collection of a more complete family history. A copy of the survey instrument is included in 
Appendix C. 
 
Statistical Analysis 
This study is exploratory and descriptive in nature; therefore, a specific sample size 
was not needed in order for outcomes to be informative, and a minimum number of 
participants was not required.  Descriptive statistics such as frequencies, means, and medians 
were used to characterize the clinical and demographic variables in the study sample.  
Proportions and percentages were calculated for first-degree relatives’ vital status, awareness 
of the variant (aware, unaware), cascade genetic testing status (tested, untested), and 
readiness for cascade genetic testing among living, untested first-degree relatives.   
To assess for potential differences between the relationship to the participant (parent, 
sibling, or child) and first-degree relatives’ awareness, cascade testing status, and readiness 
by the relative’s sex (male or female), McNemar and Friedman tests (for comparisons 
between paired or n-group-related samples of categorical variables) and Wilcoxon Signed 
Rank tests (for comparisons involving paired samples of non-parametric continuous data) 
were employed.  Potential associations between participant factors (including age, 
involvement of a genetics professional during the genetic testing process, year of genetic 
testing, and gene with variant) and first-degree relatives’ awareness and uptake of cascade 
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genetic testing were assessed using the Kruskal-Wallis (n-group comparison of 
nonparametric data) and Mann-Whitney tests (2-group comparison of nonparametric data).  
Differences in awareness among living, untested first-degree relatives was analyzed using a 
Friedman test.  A 2-sided p-value of 0.05 was considered to be statistically significant.  
Statistical analysis was performed using IBM SPSS version 24. 
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Assessing Relatives’ Readiness for Hereditary Cancer Cascade Genetic Testing 
Genetics in Medicine 
 
Abstract  
Purpose: To explore the readiness of living, untested first-degree relatives (FDRs) to have 
cascade genetic testing (CGT) for a hereditary predisposition to cancer. 
Methods: Adults with a hereditary predisposition to cancer completed an anonymous, online 
survey about their genetic testing and the vital status, awareness of the variant, and uptake of 
CGT among FDRs, and readiness for CGT among living, untested FDRs using 
Transtheoretical Model Stages of Change. 
Results: One hundred-fifty participants completed the survey and reported 825 FDRs. 
Overall, 70.3% of FDRs were aware of the variant and 30.5% had completed CGT.  Siblings 
had higher rates of awareness and CGT than parents or children (p<0.001). Relatives’ sex 
was associated with awareness and CGT; mothers were aware and had CGT at higher rates 
than fathers (p=0.049 and p<0.001), sisters were aware and had CGT at higher rates than 
brothers (p=0.041 and p=0.002), and daughters had higher rates of awareness than sons 
(p=0.038). Of 340 living, untested FDRs, 79.4% were in the precontemplation stage of 
change, with no difference by relatives’ sex or relationship to the participant.  
Conclusion:  Most living, untested FDRs were in precontemplation stage, indicating they are 
not ready or planning to have CGT within the next six months. 
Key words (5): 
Hereditary cancer, cascade testing, genetic testing, Transtheoretical model, Stage of Change 
 27 
INTRODUCTION 
Cascade genetic testing is the systematic process of providing genetic counseling and 
genetic testing to at-risk blood relatives after a germline pathogenic variant is identified in a 
family member1,2.  In the setting of hereditary cancer and tumor predisposition syndromes, 
cascade genetic testing can provide relatives with information about their variant status, the 
probability for their children to inherit a predisposition to cancer, estimates of risks to 
develop cancer or tumors, and which cancer screening and risk-reduction strategies are 
recommended. The National Comprehensive Cancer Network, the American College of 
Obstetricians and Gynecologists, the Society of Gynecologic Oncology, the Evaluation of 
Genomic Applications in Practice and Prevention, and the National Cancer Moonshots Blue 
Ribbon Panel recommend cascade genetic testing for relatives after the identification of a 
pathogenic or likely pathogenic cancer predisposition variant in a family member1,3-7.  
Although cascade genetic testing provides important information to relatives, and 
several organizations recommend testing, the uptake of cascade genetic testing within 
families with hereditary predispositions to cancer is not robust.  Most studies of cascade 
genetic testing for hereditary cancer predispositions have focused on families with Hereditary 
Breast and Ovarian Cancer (HBOC) and Lynch syndrome, which are due to inherited 
germline variants in BRCA1, BRCA2, and MLH1, MSH2, EPCAM, MSH6, and PMS2, 
respectively.  In families with HBOC or Lynch syndrome, relatives’ awareness of the 
familial variant is high (60 to 90% are aware), but rates of cascade genetic testing completion 
among at-risk relatives are lower, with rates of testing uptake ranging from 8% to 97%, with 
most studies reporting rates between 30 and 60%8,9.  Cascade genetic testing patterns in 
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families with moderate-penetrant gene variants, increasingly identified on multi-gene panel 
genetic testing, have not been characterized.   
Behavioral science theory can aid in understanding the role of determinants, barriers, 
and facilitators of cascade genetic testing within families.  The Transtheoretical Model is a 
behavioral science theory that provides a framework for understanding how people change 
health behaviors over time, and includes six stages of change through which an individual 
progresses when changing a health behavior10.  The stages of change include 
precontemplation (no intention to take action in the next six months), contemplation 
(intention to act within the next six months), preparation (intention to act within the next 30 
days), action (behavior changed for less than six months), maintenance (behavior changed for 
more than six months), and termination (no temptation to relapse to prior behavior)10,11.  
Several studies have used the Transtheoretical Model to evaluate intention to have genetic 
counseling and genetic testing among individuals with breast cancer12-14. No published 
studies have applied the stages of change to assess at-risk relatives’ readiness to undergo 
cascade genetic testing for hereditary cancer predisposition. In this study, we applied the 
Transtheoretical Model’s stages of change to explore the readiness of living, untested first-
degree relatives to undergo cascade genetic testing for a hereditary cancer predisposition 
variant identified in a family member. 
 
MATERIALS AND METHODS 
Approval for the conduct of the research study with a waiver of informed consent was 
obtained from the University of Texas Health Science Center at Houston Institutional Review 
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Board.  Data were collected using an anonymous, online Qualtrics survey.  Individuals were 
eligible to participate if they were at least 18 years of age, resided in the United States (U.S.), 
were able to complete a survey in English, reported having a pathogenic or suspected 
pathogenic variant detected in one of 73 autosomal dominantly inherited, adult-onset cancer 
predisposition genes, and could provide information about at least one blood relative.  Genes 
were selected for inclusion in the study by review of several U.S. laboratories’ clinical 
genetic testing offerings in early 2018, and autosomal dominant inheritance and adult-onset 
cancer and tumor risks were assessed by reviewing GeneReview and OMIM entries15,16.  
Participant recruitment occurred between August 1, 2018 and March 1, 2019.  The survey 
opportunity was shared by a study Twitter account and through the social media, newsletters, 
and patient forums of various hereditary cancer patient support and advocacy organizations 
who agreed to distribute the research opportunity.  Participants could enter a raffle for one of 
four $25 gift cards upon completion of the survey.  
The survey collected participant’s demographic information (age, biologic sex, race, 
ethnicity, state of residence, and if they had a cancer diagnosis), and genetic testing 
information (relevant gene, year of testing, healthcare providers who ordered the genetic 
testing and who helped to explain the results, and if the variant was confirmed or suspected 
to be maternally or paternally inherited).  Participants provided information about their first-
degree relatives including: the total count of each relative (parents, siblings, and children), 
each relative’s vital status, awareness of the variant in the family, and if the relative has had 
cascade genetic testing.  Individuals who completed cascade testing were in the “action” 
stage of the Transtheoretical Model.  Living, untested first-degree relatives’ stage of change 
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(cascade genetic testing readiness) was evaluated by, “Which of the following best describes 
your [mother/father/sister/brother/son/daughter]’s readiness for genetic testing?”  The 
available choices included: [He/She] does not plan to ever have genetic testing, [He/She] 
plans to have genetic testing but not in the next 6 months, [He/She] plans to have testing in 
the next 6 months, [He/She] plans to have genetic testing in the next month. If the relative 
planned to never have genetic testing, or planned to have testing but not in the next six 
months, they were considered to be in precontemplation stage.  Relatives who planned to 
have testing in the next six months were in contemplation stage, and relatives who planned to 
have testing in the next month were in preparation stage. The time frames were selected 
based on the Transtheoretical Model’s defined stages of change10. Participants could skip any 
survey question not directly tied to eligibility determination.   
Descriptive statistics such as frequencies, means, and medians were used to 
characterize the clinical and demographic variables in the study sample.  Proportions and 
percentages were calculated for first-degree relatives’ vital status, awareness of the variant 
(aware, unaware), cascade genetic testing status (tested, untested), and readiness for cascade 
genetic testing among living, untested first-degree relatives.  To assess for potential 
differences between the relationship to the participant (parent, sibling, or child) and first-
degree relatives’ awareness, cascade testing status, and readiness by the relative’s sex (male 
or female), McNemar and Friedman tests (for comparisons between paired or n-group-related 
samples of categorical variables) and Wilcoxon Signed Rank tests (for comparisons 
involving paired samples of non-parametric continuous data) were employed.  Potential 
associations between participant factors (including age, involvement of a genetics 
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professional during the genetic testing process, year of genetic testing, and gene with variant) 
and first-degree relatives’ awareness and uptake of cascade genetic testing were assessed 
using the Kruskal-Wallis (n-group comparison of nonparametric data) and Mann-Whitney 
tests (2-group comparison of nonparametric data).  Differences in awareness among living, 
untested first-degree relatives by their relationship type (parent, sibling, or child) were 
analyzed using a Friedman test.  A 2-sided p-value of 0.05 was considered statistically 
significant.  Statistical analysis was performed using IBM SPSS version 24. 
 
RESULTS 
At the conclusion of study recruitment, 204 individuals initiated a survey, 153 were 
eligible to participate, and 150 completed the survey and were included in analysis as 
outlined in Figure 1.  Participant demographics are reported in Table 1, whereby participants 
were predominantly female (88.0%), white (93.3%), non-Hispanic (92.7%), and more than 
half (51.3%) reported a personal history of cancer. Nearly half of participants (48.7%) 
completed genetic testing recently, between 2017 and 2019.  Genes reported to have a 
pathogenic variant by participants were varied, with the most commonly reported genes 
including CHEK2 (28.7%), BRCA1 and BRCA2 (23.3%), Lynch syndrome genes (16%), and 
SDHB and SDHC (13.3%).  Of note, only six participants reported variants in genes that have 
been associated with only female-specific cancer risks to date (four BARD1, two BRIP1), 
with all other reported genes having cancer and tumor risk implications for men and women. 
Most participants (82.0%) reported the involvement of a genetics professional (genetic 
counselor or geneticist) during their genetic testing process (pre-test, post-test, or both).   
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Relatives’ Awareness of the Familial Variant 
Participants reported 825 first-degree relatives including 296 parents, 283 siblings, 
and 246 children. Overall, 580 (70.3%) first-degree relatives were aware of the participant’s 
genetic testing results and 252 (30.5%) had completed cascade genetic testing.  The 
proportion of mothers, fathers, brothers, sisters, sons, and daughters who are aware, have had 
cascade genetic testing, and who are living and untested are provided in Table 2.  Awareness 
of the familial variant varied by relatives’ sex, with a higher proportion of mothers aware 
compared to fathers (p=0.049), sisters aware compared to brothers (p=0.041), and daughters 
aware compared to sons (p=0.038).  Awareness also varied by the relative’s relationship to 
the participant, with significantly higher awareness reported for siblings than for parents or 
children (p<0.001).  Relatives’ awareness of the variant was not statistically significantly 
different based on whether the associated variant in the family was in a high penetrant, well-
characterized cancer predisposition syndrome (HBOC or Lynch syndrome) or a lesser-
studied, rare, or moderate-penetrant gene (p=0.870).  The involvement of a genetics 
professional during the participant’s genetic testing process was not significantly associated 
with awareness in relatives (p=0.258).  The time since the participant’s genetic testing 
(recently in 2017-2019, or prior to 2017) was not associated with a significant difference in 
relatives’ awareness of the variant (p=0.345). 
 
Relatives’ Uptake of Cascade Genetic Testing 
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Completion of cascade genetic testing varied by relatives’ sex for parents and 
siblings, whereby a higher proportion of mothers had testing compared to fathers (p<0.001) 
and sisters had testing compared to brothers (p=0.002). However, there was no significant 
difference in cascade genetic testing in daughters compared to sons (p=0.178).  Cascade 
genetic testing also varied by relationship to the participant, whereby siblings had 
significantly higher rates of cascade genetic testing than parents or children (p<0.001).  
Cascade genetic testing among first-degree relatives was higher when participants completed 
genetic testing prior to 2017 (mean testing rate of 42.5%) as compared to those with more 
recent testing (mean testing rate of 24.3%) (p=0.003).  First-degree relatives’ cascade genetic 
testing rates were not significantly different based on the cancer predisposition syndrome 
(HBOC and Lynch syndrome, versus all other genes) (p=0.376), or based on the involvement 
of a genetics professional in the participant’s genetic testing process (p=0.751).   
 
Relatives’ Readiness for Cascade Genetic Testing 
Of the total 340 first-degree relatives who were living and untested, the majority 
(270, 79.4%), were in the precontemplation stage of change, and were either planning to 
never have cascade genetic testing or were not planning to have cascade genetic testing in the 
next six months.  Only 23 (6.8%) first-degree relatives were in the contemplation stage and 
planning to have cascade genetic testing in the next six months, and 15 (4.4%) were in the 
preparation stage and planning to have cascade genetic testing in the next month.  The 
remaining 32 living, untested first-degree relatives had no status reported by the participant.  
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Unlike awareness and cascade genetic testing status, there were no statistically 
significant differences in readiness for cascade genetic testing by sex among living, untested 
relatives when comparing male first-degree relatives to female first-degree relatives 
(p=0.892), or when comparing mothers and fathers (p=0.317), brothers and sisters (p=0.655), 
or sons and daughters (p=0.180).  There was also no statistically significant difference in 
readiness by the relatives’ relationship to the participant, as living, untested parents, siblings, 
and children were all primarily in the precontemplation stage (p=0.646).   
Of note, living, untested children in the precontemplation stage were often 
categorized as planning to pursue cascade genetic testing but not within the next six months 
(61.2%), whereas most parents and siblings in the precontemplation stage were planning to 
never have cascade genetic testing (78.7% and 50.0%, respectively).  One potential reason 
for this difference could be relative’s age, since the age of a child is a relevant consideration 
in the recommendation of cascade genetic testing for adult-onset cancer predisposition.  We 
evaluated this consideration from the perspective of participant age, and found that 
participants who were under age 50 had more untested children compared to participants age 
50 or older (p=0.007), which suggests that younger participants’ children may be under 18 
and not yet recommended or ready to pursue cascade genetic testing.    
 Another relevant consideration for the readiness of parents to undergo cascade 
genetic testing is whether the variant was inherited from the participant’s mother or father.  
In some families, the inheritance of a variant is confirmed by the results of cascade genetic 
testing in a parent or a more distant (second or third degree) relative, the inheritance may be 
suspected based on family history of cancer, or the inheritance may be unknown due to lack 
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of family history of cancer and lack of cascade genetic testing.  Evaluating the relationship 
between inheritance and the readiness of parents to have cascade genetic testing was 
complicated by the significantly higher rates of cascade genetic testing among mothers, and 
the high proportion of living, untested parents in the precontemplation stage, in all 
inheritance scenarios.  Among participants who reported that the gene variant was confirmed 
or likely maternally inherited, three of three (100%) living and untested mothers, and 26 of 
29 (90.0%) living and untested fathers were in the precontemplation stage.  Participants who 
reported that the variant was confirmed or likely paternally inherited had 19 of 20 (95%) 
living, untested mothers and 10 of 11 (91.0%) living, untested fathers in the 
precontemplation stage. 
Awareness of the variant is another relevant consideration in the readiness for cascade 
genetic testing.  Most (79.7%) living, untested first-degree relatives were aware of the variant 
in the family, which did not vary by relationship (parent, sibling, or child) to the participant 
(p=0.368).  This finding suggests that awareness was not a major factor contributing to the 
lack of readiness to pursue cascade genetic testing among living, untested relatives. 
 
DISCUSSION 
Consistent with prior studies, 70.3% of first-degree relatives were aware of the 
hereditary risk for cancer in their family, but only 30.5% had completed cascade genetic 
testing.  Also consistent with prior studies, these rates varied by relatives’ sex, with female 
relatives having higher rates of awareness and cascade genetic testing as compared to male 
relatives. There was no difference in first-degree relative’s awareness of the variant based on 
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how recently the participant completed genetic testing, which aligns with studies reporting 
that individuals communicate their results to close relatives within 48 hours to one month 
after receipt of a positive test result17,18. 
Our study found that only 11.2% of first-degree relatives who had not completed 
cascade genetic testing were ready and planning to have testing in the near future (within the 
next one to six months).  Most first-degree relatives were in the precontemplation stage of 
change for cascade genetic testing, which is the Transtheoretical Model stage of change with 
the least readiness for action or behavior change. The majority of living, untested first-degree 
relatives were aware of the variant, suggesting that this was not a likely cause for the lack of 
cascade testing readiness.  Notably, readiness of relatives to undergo cascade genetic testing 
did not vary by the relatives’ sex or relationship to the participant (parent, sibling, or child).  
Lack of cascade genetic testing for hereditary predispositions to cancer among at-risk 
relatives is a concern among scientists, clinicians, and patient advocates, primarily due to the 
missed opportunity to reduce cancer incidence and mortality through recommended cancer 
screening, risk-reduction, and use of targeted cancer therapies. Interventions to increase 
communication of risk-information within families and to improve access to genetic testing 
have had limited or null effects on cascade genetic testing outcomes, have focused 
predominantly on well-characterized hereditary cancer syndromes (HBOC and Lynch 
syndrome), and may not translate across settings due to differences in country and state laws, 
health care policies, and care-delivery infrastructure2,19-28.  Although environmental barriers 
to cascade genetic testing in the U.S. have changed, leading to increased access to genetic 
counseling and testing, decreased genetic testing costs, improved protections against genetic 
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discrimination through the Genetic Information Nondiscrimination Act, and increased rates 
of health insurance coverage secondary to the Affordable Care Act, cascade genetic testing 
rates have not noticeably increased.  
The results of this study may guide future efforts to increase rates of cascade genetic 
testing by encouraging greater consideration of the stages and processes of behavior change 
and the family members who may benefit from cascade genetic testing interventions.  For 
example, sharing of genetic test results and rates of awareness of a variant in a family are 
relatively high, and represent an important precursor to cascade genetic testing.  However, 
rates of awareness are lower among male relatives, prior efforts to improve communication 
within families may not be reaching male relatives effectively, and communication-focused 
interventions alone have not significantly influenced the cascade genetic testing decision-
making and behavior change processes of relatives.  Similarly, interventions that provide 
more accessible genetic counseling and genetic testing to at-risk relatives may benefit the 
relatives actively seeking cascade genetic testing in the contemplation and preparation stages, 
which represent only 11% of living, untested relatives in our study.  Focusing on increasing 
accessibility of genetic testing is unlikely to address the needs of at-risk relatives in the 
precontemplation stage.  Comprehensive, theoretically grounded, and tailored approaches in 
cascade genetic testing intervention and research program design are needed. 
A benefit of using the Transtheoretical Model to study behavior change include the 
stage-matched processes of change, and relevance of self-efficacy, or the confidence to make 
a behavior change; and decisional balance, the perceived pros and cons of behavior change, 
throughout an individual’s behavior change process10. Prior studies of psychosocial factors 
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involved in genetic testing decision-making have consistently identified decisional balance 
(perceived benefits and perceived barriers and risks) as an important determinant of genetic 
testing29.  The Transtheoretical Model processes of change associated with moving 
individuals from the precontemplation stage toward the contemplation stage include: 
consciousness raising, environmental reevaluation, and dramatic relief10. Consciousness 
raising includes activities that increase an individual’s awareness of the health problem 
(hereditary cancer predisposition) and the health behavior (cascade genetic testing), the 
causes of the health problem, the consequences performing the health behavior, and the 
treatments and risk-reduction options for those with a hereditary cancer predisposition10. Our 
study found that first-degree relatives have high rates of awareness of the variant in the 
family, however, it is unknown whether relatives are equally aware of the consequences of 
cascade genetic testing, treatment and management options for hereditary predisposition to 
cancer, and other implications of cascade genetic testing for themselves and their family.  A 
second process, environmental reevaluation, includes both cognitive and affective self-
assessments about how an individual’s behavior impacts others, and how the individual may 
serve as a role model for others through their behavior and actions10.  For cascade genetic 
testing, environmental reevaluation-based interventions may include guided discussion and 
reflection on family dynamics and support systems, assessing the impact of not having 
cascade genetic testing on their current or future children, or considering how relatives who 
have tested positive for the variant or who are undergoing cancer treatment may perceive 
disinterest in cascade testing by the individual.  Sharing stories of other families facing 
similar hereditary cancer predispositions and cascade genetic testing decisions, and how 
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cascade genetic testing has affected relationships between relatives, spouses, and other 
members of their social network could support the environmental reevaluation process.  
Finally, dramatic relief is a process to increase emotional experiences associated with the 
behavior change10.  Interventions using dramatic relief to promote readiness for cascade 
genetic testing could include personal testimonies or family stories about the emotional 
benefits (relief of knowing, empowerment to manage one’s health, decreased uncertainty) of 
learning one’s variant status and taking action to prevent cancer in themselves and their 
family.  These Transtheoretical Model constructs and processes of change can be used to 
design and measure the effect of interventions to promote cascade genetic testing behavior 
within families, especially among relatives in precontemplation stage. 
 
Study Limitations 
Since the study was anonymous and designed to be simple and quick to complete for 
participants, we were unable to verify the genetic testing results of participants, collect ages 
and cancer histories for each relative, or evaluate if multiple participants were from the same 
family.  The participants in our study may not be representative of families with hereditary 
cancer predisposition, in part due to the study recruitment strategy that relied upon social 
media platforms, and hereditary cancer awareness and advocacy organizations, which may 
serve specific populations of individuals with hereditary predisposition to cancer.  
Participants may have erroneously or accidentally misreported information about their 
relatives’ awareness, testing, or readiness status.  To minimize the data entry burden on 
participants, we did not collect the ages, cancer history, or other determinants of cascade 
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genetic testing for relatives. Future studies may consider collecting additional data points 
about relatives, and may investigate pathways for relatives to self-report their own 
information, to ensure the accuracy of cascade genetic testing status and readiness.   
Future studies of cascade genetic testing should incorporate behavioral science 
theories and frameworks in order to evaluate the interaction of relevant psychosocial 
constructs, such as decisional balance, self-efficacy, and stage of change over time.  
Validated instruments exist for the measurement of these variables; however, these 
instruments have not been adapted and validated in populations with hereditary cancer 
syndromes, representing an opportunity for collaboration between behavioral scientists and 
genetics professionals.  Future programs seeking to impact cascade genetic testing behaviors 
should incorporate behavioral science theories, and apply frameworks such as intervention 
mapping, in the development of programs30.  Intervention mapping can help link 
hypothesized determinants and psychosocial factors to the development of evidence-based 
interventions and measurement of outcomes. 
Given the large proportion of living, untested relatives found to be in 
precontemplation stage in our study, future studies should further evaluate the factors 
involved in the decision to forgo or postpone cascade genetic testing, relatives’ perceived 
importance of each factor in the decision-making process, and the potential for 
misinformation to influence an individual’s decision about cascade genetic testing.  
Assessment of the information and counseling needs of relatives in precontemplation stage 
may aid in the development of appropriate interventions and genetic counseling tools for 
families to support informed decision-making processes. 
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 Figure 1. Participant Survey Responses and Reasons for Ineligibility   
 
  
204 Survey responses 
153 Eligible participants 
51 Ineligible 
• 8   No age provided 
• 9   No state selected 
• 16 No genetic testing performed 
• 9   No variant found on testing 
• 9   No gene selected 
150 Included in analysis 
3 Surveys provided no family history information 
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Table 1. Participant Demographics and Genetic Testing Characteristics 
Characteristic N % 
Age (years) Mean: 46.2  Range: 19-78 
Sex Male 18 12.0 
 Female 132 88.0 
Race White 140 93.3 
 Other race(s)a 10 6.7 
Ethnicity b Non-Hispanic 139 92.7 
 Hispanic 10 6.7 
History of Cancer Diagnosis   
 Yes 77 51.3 
U.S. State of Residence (U.S. Census Region)   
 South 43 28.7 
 Northeast 42 28.0 
 Midwest 33 22.0 
 West 32 21.3 
Gene with Variant   
 CHEK2 43 28.7 
 BRCA1 20 13.3 
 SDHB 16 10.7 
 BRCA2 15 10.0 
 PMS2 10 6.7 
 MSH6 6 4.0 
 PALB2 5 3.3 
 ATM 5 3.3 
 MLH1 4 2.7 
 MSH2 4 2.7 
 BARD1 4 2.7 
 SDHC 4 2.7 
 BAP1 3 2.0 
 PTEN 3 2.0 
 Otherc 8 5.3 
Year of Genetic Testing   
 2007 and prior 5 3.3 
 2008-2010 10 6.7 
 2011-2013 14 9.3 
 2014-2016 48 32.0 
 2017-2019 73 48.7 
a. Other races included: 2 Black/African American, 2 American Indian/Alaska Native, 1 Asian 
Indian, 1 Chinese, 4 Other 
b. 1 selected “prefer not to answer” and was not included into either Hispanic or Non-Hispanic 
c. Other genes included: 2 BRIP1, 2 AXIN2, 1 APC, 1 NF1, 1 TP53, and 1 VHL 
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Table 2. Relatives’ Awareness and Uptake of Cascade Genetic Testing  
Relation to 
participant  
Total 
Number 
Aware of Familial 
Variant 
Completed Cascade 
Genetic Testing 
Alive, 
Untested 
n % n % n % 
Father 146 77 52.7 17 11.6 55 37.7 
Mother 150 93 62.0 48 32.0 39 26.0 
Brother 167 120 71.9 46 27.5 67 40.1 
Sister 116 107 92.2 76 65.5 27 23.3 
Son 132 93 70.5 32 24.2 78 59.1 
Daughter 114 90 78.9 33 28.9 74 64.9 
Sum: 825 580 70.3 252 30.5 340 41.2 
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CONCLUSION 
 This study is the first to describe the readiness for hereditary cancer cascade genetic 
testing among living, untested first-degree relatives using the Transtheoretical Model stage of 
change constructs.  The study found that most first-degree relatives are in precontemplation 
stage and not planning to pursue cascade genetic testing in the next 6 months.   The 
proportion of eligible, at-risk first-degree relatives in precontemplation stage is informative 
for the design and implementation of future research, determination of which first-degree 
relatives are participating and benefiting from the existing cascade genetic testing initiatives, 
and how to tailor genetic counseling for cascade genetic testing to better serve the population 
of individuals in precontemplation stage.  Relatives who are in the precontemplation stage of 
change may benefit from more targeted cascade genetic testing interventions that apply the 
Transtheoretical Model processes of change.   
 An important strength of this study was the acceptability of an anonymous, online 
survey by study participants.  Over 150 individuals sought to participate in our study, and 
participants included in the study analysis were diverse in terms of age, location, and 
hereditary cancer predisposition syndrome. Most participants completed their survey in under 
10 minutes.  An online and social-media directed recruitment and survey-delivery approach 
may provide greater opportunities for patients and families to participate in hereditary cancer 
research.   
 Another strength of the study is the application of behavioral science theory and 
psychosocial constructs in the setting of hereditary cancer and cascade genetic testing.  Prior 
studies of cascade genetic testing have not consistently applied theories to their study design, 
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nor measured psychosocial variables that are relevant to participant’s behavior and decision-
making.  Applying the Transtheoretical Model stages of change to cascade genetic testing 
behavior has provided an opportunity to learn new and clinically relevant information about 
hereditary cancer families, and to identify opportunities for future research. 
 The major limitations of the study are primarily due to study design.  First, participant 
anonymity restricted the collection of genetic testing results to confirm mutation status. 
Further, we were unable to determine if multiple relatives from a single family participated in 
the study.  The survey was brief and simple, which resulted in limiting or excluding the 
collection of other relevant variables such as relatives’ ages, the outcomes of cascade genetic 
testing, and sociodemographic factors such as income, education, and health insurance status.  
Additionally, participants reported the status of relatives, rather than collecting this 
information directly from relatives, which may introduce the possibility for erroneous 
information.   
Further research is needed to understand the decision-making process, the 
information used to form decisions about cascade genetic testing, and to identify what 
resources would help support informed decision-making within the population of at-risk 
individuals in the precontemplation stage. Future studies may wish to explore opportunities 
to interact with living, untested first-degree relatives to study the interaction of 
environmental and personal psychosocial determinants of cascade genetic testing.  The field 
of genetic counseling and hereditary cancer genetics should incorporate behavioral science 
theory, frameworks, and methods into the design of future interventions to improve cascade 
genetic testing. 
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Appendix B: Study Recruitment Materials 
Study introduction email message to organizations: 
 
My name is Erica Bednar, and I am a cancer genetic counselor at the University of Texas 
MD Anderson Cancer Center and a student at the UTHealth School of Public Health.  As part 
of my Public Health degree, I have created a research study to better understand and assess 
the “readiness” of relatives to undergo genetic testing (cascade testing) for a known mutation 
in the family associated with a hereditary cancer or tumor syndrome.  I am contacting you to 
ask for your assistance in sharing this survey with members of your group or organization. 
 
Cascade testing is often recommended for family members so that they can determine their 
cancer risks.  If relatives have inherited increased risks to develop cancer, they can work with 
their doctors to prevent cancer or reduce their risks.  Prior studies have found that the current 
strategies in the United States to encourage family members to have cascade testing do not 
work well and can be a burden on patients and families.   
 
This research study will include men and women who have a mutation in one of several 
inherited cancer/tumor genes.  The research study uses a theory called the Transtheoretical 
model to explore what “stage of readiness” relatives are in regarding having cascade testing.  
When someone is in a “stage of readiness,” there are communication strategies that may be 
helpful.  Our hope is that the findings of this research study will be used to develop tools for 
the hereditary cancer community, doctors, and genetic counselors to make cascade testing 
communication more effective.  Additionally, participants who participate in the study and 
complete the survey will have the opportunity to enter a raffle for a gift card.   
 
This research study is being performed to fulfill a thesis requirement for a Master’s of Public 
Health degree and has been approved by the UTHealth Institutional Review Board (IRB).  
This survey is anonymous and does not collect any identifying information.  Only my 
advisors at UTHealth and I will have access to the data.  The study is funded by myself, with 
no assistance or funds from genetic testing laboratories, genetic counseling companies, or my 
employer.  When the study is completed, we intend to publish the results so that participants 
can read about the findings and be acknowledged for their contributions. 
 
If you are able to distribute the survey for the research study, please let me know, as I would 
greatly appreciate your support!  The link to the survey is here: (include Qualtrics link) and 
will be active between (Start date – End date).  If you have any questions or concerns about 
the survey or sharing it with your community, please feel free to contact me. 
 
Thank you very much, 
 
Erica Bednar, MS, CGC, MPH Student at UTHealth School of Public Health 
Email: Erica.m.bednar@uth.tmc.edu     
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Social media advertising materials 
No character limit (email, website, Facebook, other):   
Have you had genetic testing to determine if a risk for cancer runs in your family?  
Did you receive a positive result?  Was a mutation found in a cancer predisposition gene on 
your genetic testing?  Do you have family members who are recommended to have genetic 
testing for this mutation?   
Researchers at UTHealth are working with people like to you to learn more about 
whether family members are ready to have genetic testing for a mutation found in one of 
their relatives (called cascade testing).  This research study is an anonymous survey and has 
been approved by the UTHealth Institutional Review Board.  At the end of the survey you 
can enter for a chance to win a gift card!  Learn more here: /link/ 
 
280 characters (Twitter):  
Your inherited cancer genetic testing results are positive. You were told that your family 
members should have genetic testing too. Help us learn how ready your family members are 
to have genetic testing by completing this anonymous research survey: /link/ 
 
Do you have an inherited gene mutation that increases your chance to develop cancer?  Are 
family members considering genetic testing to learn their risks?  Take this anonymous 
research survey to help us learn about family member readiness to have cascade testing: 
/link/ 
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Have you tested positive for a hereditary cancer gene mutation? We want to learn if family 
members are ready to have genetic testing too.  You can help by participating in our research 
study by taking this anonymous survey, with a chance to win a gift card.  Learn more here: 
/link/ 
 
Was an inherited mutation in *gene from list* found on your genetic testing?  We are 
studying if family members are ready to have genetic testing for the *gene* mutation.  You 
can help our research study by taking this anonymous survey + enter to win a gift card: /link/ 
 
Cascade testing can provide important information for at-risk relatives when an inherited risk 
for cancer has been found in the family.  Have you tested positive for an inherited risk for 
cancer? Help us learn more about your family’s readiness to have cascade testing by taking 
our research survey here: 
 
If you have tested positive for a gene mutation that increases your risk to develop cancer, 
your relatives may have the mutation too.  We are seeking your help to better understand if 
relatives are ready to have genetic testing for mutations that run their family.  Find out more 
about our research study here: 
 
Do you have an inherited risk for cancer found on genetic testing, and want to contribute to 
research? Check out our study! We are using a survey to learn if relatives are ready to have 
genetic testing for an inherited risk for cancer that is in their family. Find out more, here: 
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140 characters (Twitter): 
Have you tested positive for hereditary cancer risks? We are studying how family members 
have genetic testing using an anonymous research survey.  Learn more here: /link/ 
 
Social media hashtags that may be added to social media ads to increase study dissemination: 
#gencsm (genetic cancer 
social media) 
#cowdensyndrome #lynchsyndrome 
#/gene list/ #hereditarycancer #GeneticCancers 
#hereditarycancersyndrome #GCChat (Genetic 
counselor chat) 
#PancChat (Pancreatic 
cancer chat) 
#bcsm (breast cancer social 
media) 
#breastcancer #pancreaticcancer 
#gyncsm (gynecologic 
cancer social media) 
#ovariancancer #endometrialcancer 
#uterinecancer #crcsm (colorectal cancer 
social media) 
#coloncancer 
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Raffle Winner email 
Good morning/afternoon, 
 
Thank you very much for completing the survey about family members’ readiness to have 
genetic testing.   
 
You have been selected as a winner of the gift card raffle for this study – Congratulations!   
 
Please reply by (Date) with your gift card receipt preference (electronic via email, or by mail 
if you would like to provide your mailing address).  If we do not receive a response from you 
by this time, a new winner will be selected for the raffle. 
 
Sincerely, 
The study team at UTHealth School of Public Health 
 
 
 
 
 
  
 58 
Appendix C.  Survey Instrument 
Survey Page 1: Study description and agreement to participate  
 
It is estimated that 5-10% of all cancers are inherited or hereditary: due to an underlying 
genetic change (mutation) that is passed down from generation to generation in a 
family.  After a mutation is found, blood relatives of the person with the mutation may decide 
to have genetic testing for the specific gene mutation identified in their family. This is called 
"cascade testing." 
 
Cascade testing can provide important information.  Relatives who test positive for the 
mutation may have higher risks to develop cancer or tumors.  Relatives who test negative for 
the mutation typically have lower cancer risks.  The results of cascade testing can help people 
and their doctors determine the best options for cancer screening or surgery to reduce their 
chance to develop cancer.   
 
Not all relatives have cascade testing, even if it is recommended by a doctor.  This survey 
will count the number of relatives that you have, and will ask if they have had cascade 
testing.  For relatives who have not had cascade testing, the survey will ask how ready the 
family member is to have testing.  The results from this survey will help us to better 
understand cascade testing in families and may help us develop resources and tools to help 
family members decide if cascade testing is something they would like to do and how testing 
could help them. 
 
To participate in this study, you must: 
+ Be 18 years of age or older 
+ Live in the United States 
+ Be able to complete a survey in English 
+ Have at least one blood-relative (such as a parent, sibling or child) 
+ Have a positive genetic testing result for an inherited cancer or tumor condition  
A positive result is sometimes written as a "deleterious", “pathogenic”, or "suspected 
deleterious/pathogenic" mutation on a laboratory report.  Testing for inherited cancer is 
typically done on blood, saliva, or a skin biopsy.   
 
The time needed to complete the survey will depend on how many relatives you have (larger 
families may require more time than smaller families).  If you are unable to complete the 
survey in one sitting you may close the survey and return to it by re-clicking the survey link 
while using the same phone or computer that you used to start the survey. 
 
This study has been approved by the University of Texas Health Science Center at Houston 
Institutional Review Board.  Your participation in this study is entirely optional.  This survey 
will not collect any information that will identify who you or who your family members 
are.  The survey is anonymous and confidential.  Only the study team will have access to 
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survey responses.  After the study is completed, all data collected by this survey will be 
destroyed. 
 
This survey may include questions that make you feel uncomfortable, and you can skip any 
questions that you do not want to answer, unless they are required to determine study 
eligibility.  Completing this survey may not have any direct benefits to you.  At the 
conclusion of the survey, you will have the opportunity to enter into a raffle to win a $25 gift 
card.  Entering the raffle is not required.  The chance of winning the raffle will depend on the 
number of people who complete the survey and enter the raffle.   
 
If you have any concerns or problems completing the survey, please contact the study team at 
(include study twitter account, study facebook account). 
 
By clicking “I agree” below, you agree to participate in this study 
• I agree 
• I do not agree 
 
Qualtrics: 
Response is required 
Question type: Multiple choice > Single answer 
Responses:  “I agree” will take participant to page 2 of survey. 
“I do not agree” = ineligible and will direct participant to last page of survey, 
thanking them for their interest in the study. 
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Survey Page 2:  Demographic characteristics 
 
1. How old are you? 
Qualtrics: 
Response is required 
Question type: Text Entry > Single line 
If number entered is <18 = ineligible and will direct participant to last page of survey, 
thanking them for their interest in the study 
Invalid responses are numbers under 18 and numbers over 120 
 
2. Please select the state where you currently live 
Qualtrics: 
Responses:  50 U.S. states 
Response is required 
Question type: Multiple choice > Dropdown list 
 
3. What is your biologic sex (assigned at birth)? 
Qualtrics: 
Responses: Male, Female, Other, Prefer not to answer 
Question type: Multiple choice > Single answer 
 
4. How do you describe your race? Check all that apply 
Qualtrics: 
Responses (include current/proposed U.S. Census categories):  White, Black or African 
American, American Indian or Alaska Native, Native Hawaiian or Pacific Islander, Asian 
Indian, Japanese, Chinese, Korean, Filipino, Vietnamese, Samoan, Middle Eastern, 
African, Other/Prefer not to answer 
Question type: Multiple choice > Multiple answer 
 
5. Are you of Hispanic or Latino origin? 
Qualtrics: 
Responses include: Yes, No, Prefer not to answer 
Question type: Multiple choice > Single answer 
 
6.  Have you ever been diagnosed with cancer? 
Qualtrics: 
Responses include: Yes, No 
Question type: Multiple choice > Single answer 
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Survey Page 3:  Genetic Testing 
 
7. Have you had genetic testing for a hereditary cancer or tumor condition? 
Genetic testing for inherited or hereditary cancers is typically performed on 
blood, saliva, or a skin biopsy. 
Qualtrics: 
Responses include: Yes, No 
Response is required 
Question type: Multiple choice > Single answer 
If response = no = ineligible and will take participant to last page of survey, thanking 
them for their interest in the study. 
 
8. Did you receive a “positive” genetic test result? 
A “positive” result means that a mutation has been found.  Laboratory results 
may include wording such as a “deleterious” or “pathogenic” mutation, or a 
“suspected deleterious” or “suspected pathogenic” mutation.  Results that 
identify a “variant of uncertain significance” are not considered positive 
results. 
Qualtrics: 
Responses include: Yes, No 
Response is required 
Question type: Multiple choice > Single answer 
If response = no = ineligible and will take participant to last page of survey, thanking 
them for their interest in the study. 
 
9.  Which of the following genes were “positive” for a mutation on your 
genetic testing? 
Please select only one.  If you had a “positive” result for more than one gene 
mutation, please select only of the genes from the list. 
Qualtrics: 
Responses include: AIP, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, 
BRCA2, BRIP1, CDC73 (HRPT2), CDH1, CDK4,CDKN1B, CDKN2A, CEBPA, CHEK2, 
DDX41, DICER1, EGFR, EPCAM, ETV6,FH, FLCN, GALNT12, GATA2, GREM1, 
HOXB13, KIT, LZTR1, MEN1, MET, MITF, MLH1, MSH2, MSH6, NBN, NF1, NF2, 
NTHL1, PALB2, PDGFRA,PMS2, POLE, POLD1, POT1, PRKAR1A, PTCH1, PTEN, 
RAD51C, RAD51D, RB1, RECQL, RET, RUNX1, SDHA, SDHB, SDHC, SDHAF2, 
SMAD4, SRP72, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, 
WRN, XRCC2  (Gene categories will be included in analysis but not survey) 
Response is required 
Question type: Multiple choice > Dropdown list 
 
10.  What year did you have genetic testing for a hereditary cancer or tumor 
condition? 
Qualtrics: 
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Responses include: “before 2000”, 2001, 2002…2018, 2019” 
Question type:  Multiple choice > Dropdown list 
 
 
11. Who helped to order your genetic testing? 
Qualtrics: 
Responses include: Genetic counselor, Genetics doctor (geneticist), Cancer doctor 
(oncologist), Family doctor or primary care provider, Gynecologist, Research study, Self 
(ordered testing online, such as 23&Me or Color), Other 
Question type: Multiple choice > Multiple answer  
 
12.  Who helped to explain the results of your genetic testing? 
Qualtrics: 
Responses include: Genetic counselor, Genetics doctor (geneticist), Cancer doctor 
(oncologist), Family doctor or primary care provider, Gynecologist, Doctor’s office staff 
(such as a nurse or physician assistant), Research study, Self (received results online, like 
through 23&Me or Color), Other 
Question type: Multiple choice > Multiple answer  
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Survey Page 4:  Family Members (First-Degree Relatives) 
 
“Please complete the following questions about your family to the best of your knowledge. 
Some people may find it helpful to talk with their relatives as they complete this portion of 
the survey.  You are not required to communicate with relatives in order to complete these 
questions. 
 
Please include only family members who are related to you by blood (biological relatives).  
Do not include relatives who are related to you through marriage (spouses, step-children), or 
adopted into your family.” 
 
First-Degree Relatives 
  
13.  Do you know who your birth parents are? 
a) Yes, I know my birth mother and birth father 
b) I know my birth mother, but not my birth father 
c) I know my birth father, but not my birth mother 
d) I do not know my birth parents 
Qualtrics: 
Question type: Multiple choice > Single answer 
Logic: If D selected: move to Sibling questions   
If A, B, or C selected: Parent Questions  
 
Parent Questions: 
14.  Check all of the boxes that apply to your (Mother/Father) 
a) She/He knows about my genetic testing result 
b) She/He has had genetic testing 
c) She/He is alive 
Qualitrics: 
Question type: Multiple choice > Multiple answer 
Logic: if B is not selected and C is selected: Stages Question 
   
Stages Question 
15.  Which of the following best describes your Mother/Father’s readiness for 
genetic testing? 
a) She/He do not plan to ever have genetic testing 
b) She/He plans to have genetic testing, but not in the next 6 months 
c) She/He plans to have genetic testing in the next 6 months 
d) She/He plans to have genetic testing in the next month 
Qualtrics: 
Question type: Multiple choice > Dropdown list 
 
Siblings Questions 
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Full-siblings are brothers and sisters who share both the same mother and the same father as 
you. For the next set of questions, please count the number of full-siblings that you have, 
including those who are living and those who have died.   
 
16.  How many full-brothers do you have? 
a) 0 – 10 (options) 
17. How many full-sisters do you have? 
a) 0 – 10 (options) 
Qualtrics 
Question type: Multiple choice > Dropdown list 
Logic:    
(Per sibling type) answers 1 through 10 will display as up to 10 columns:  
 
18.  Please provide the following information about your brother(s) 
 Brother 1 Brother 2 Brother 3 Brother 4 Brother 5 
They know about my genetic 
test results Yes/No Yes/No Yes/No Yes/No Yes/No 
They have had genetic testing Yes/No Yes/No Yes/No Yes/No Yes/No 
They are alive Yes/No Yes/No Yes/No Yes/No Yes/No 
 
 
19.  Please provide the following information about your sister(s) 
 Sister 1 Sister 2 Sister 3 Sister 4 Sister 5 
They know about my genetic 
test results Yes/No Yes/No Yes/No Yes/No Yes/No 
They have had genetic testing Yes/No Yes/No Yes/No Yes/No Yes/No 
They are alive Yes/No Yes/No Yes/No Yes/No Yes/No 
 
Qualtrics 
Question type: Side by side 
Logic: (Per sibling) No Genetic Testing + Alive: that sibling will display as a row  
 
 
You noted that the sister(s) below have not yet had genetic testing.  If no sisters 
appear below this question, please proceed to the next question. 
20.  Which of the following categories best describes their readiness for 
genetic testing? 
Sister 1 a) They do not plan to ever have genetic testing 
b) They plan to have genetic testing, but not in the next 6 months 
c) They plan to have genetic testing in the next 6 months 
d) They plan to have genetic testing in the next month 
Sister 2 a-d as above 
Sister 3 a-d as above 
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Sister 4 a-d as above 
Sister 5 a-d as above 
Sister 6 a-d as above 
Sister 7 a-d as above 
Sister 8 a-d as above 
Sister 9 a-d as above 
Sister 10 a-d as above 
 
You noted that the brother(s) below have not yet had genetic testing. If no brothers 
appear below this question, please proceed to the next question. 
21.  Which of the following categories best describes their readiness for 
genetic testing? 
Brother 1 a) They do not plan to ever have genetic testing 
b) They plan to have genetic testing, but not in the next 6 months 
c) They plan to have genetic testing in the next 6 months 
d) They plan to have genetic testing in the next month 
Brother 2 a-d as above 
Brother 3 a-d as above 
Brother 4 a-d as above 
Brother 5 a-d as above 
Brother 6 a-d as above 
Brother 7 a-d as above 
Brother 8 a-d as above 
Brother 9 a-d as above 
Brother 10 a-d as above 
Qualtrics 
Question type: Matrix Table > Likert > Dropdown list 
 
Children Questions 
22. How many sons do you have? 
a) 0 -10 (options) 
23. How many daughters do you have? 
a) 0 – 10 (options) 
Qualtrics 
Question type: Multiple choice > Dropdown list 
Logic:   
(Per child type) answers 1 through 10 will display as up to 10 columns:  
 
24.  Please provide the following information about your son(s) 
 Son 1 Son 2 Son 3 Son 4 Son 5 
They know about my genetic 
test results Yes/No Yes/No Yes/No Yes/No Yes/No 
They have had genetic testing Yes/No Yes/No Yes/No Yes/No Yes/No 
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They are alive Yes/No Yes/No Yes/No Yes/No Yes/No 
 
 
25.  Please provide the following information about your daughter(s) 
 Daughter 
1 
Daughter 
2 
Daughter 
3 
Daughter 
4 
Daughter 
5 
They know about my genetic 
test results Yes/No Yes/No Yes/No Yes/No Yes/No 
They have had genetic testing Yes/No Yes/No Yes/No Yes/No Yes/No 
They are alive Yes/No Yes/No Yes/No Yes/No Yes/No 
 
Qualtrics 
Question type: Side by side 
Logic: (Per child) No Genetic Testing + Alive: that child will display as a row  
 
You noted that the son(s) below have not yet had genetic testing.  If no sons appear 
below this question, please proceed to the next question. 
26.  Which of the following categories best describes their readiness for 
genetic testing? 
Son 1 e) They do not plan to ever have genetic testing 
f) They plan to have genetic testing, but not in the next 6 months 
g) They plan to have genetic testing in the next 6 months 
h) They plan to have genetic testing in the next month 
Son 2 e-h as above 
Son 3 e-h as above 
Son 4 e-h as above 
Son 5 e-h as above 
Son 6 e-h as above 
Son 7 e-h as above 
Son 8 e-h as above 
Son 9 e-h as above 
Son 10 e-h as above 
 
You noted that the daughter(s) below have not yet had genetic testing. If no daughters 
appear below this question, please proceed to the next question. 
27.  Which of the following categories best describes their readiness for 
genetic testing? 
Daughter 1 e) They do not plan to ever have genetic testing 
f) They plan to have genetic testing, but not in the next 6 months 
g) They plan to have genetic testing in the next 6 months 
h) They plan to have genetic testing in the next month 
Daughter 2 e-h as above 
Daughter 3 e-h as above 
 67 
Daughter 4 e-h as above 
Daughter 5 e-h as above 
Daughter 6 e-h as above 
Daughter 7 e-h as above 
Daughter 8 e-h as above 
Daughter 9 e-h as above 
Daughter 10 e-h as above 
 
Qualtrics 
Question type: Matrix Table > Likert > Dropdown list 
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Survey Page 5:  Family members (Second and Third-degree relatives) 
Please complete the following questions about your family to the best of your knowledge. 
Some people may find it helpful to talk with their relatives as they complete this portion of 
the survey. You are not required to communicate with relatives in order to complete these 
questions. 
 
Please include only family members who are related to you by blood (biological relatives). 
Do not include relatives who are related to you through marriage (spouses, step-children), or 
adopted into your family. 
 
Second and Third-Degree Relatives 
 
28.  Do you know from which side of your family that you inherited the gene 
mutation? 
a)  The mutation is from my mother’s family (mother or other maternal relative has 
tested positive) 
b) The mutation is from my father’s family (father or other paternal relative has 
tested positive) 
c) The mutation is probably from my mother’s family, but this is not confirmed 
d) The mutation is probably from my father’s family, but this is not confirmed 
e) The mutation was not inherited, and is new in me (mother and father were tested 
and they do not have the mutation) 
f) I do not know 
 
Qualtrics 
Question type: Multiple choice > single answer 
If A, C, or F selected: show maternal questions 
If B, D, or F selected: show paternal questions 
 
Second and Third-Degree Relatives 
 
29.  Please provide the number of relatives from your maternal (Mother’s) 
side of the family for each of the categories 
 Total (living 
and 
deceased) 
Know about the 
mutation in the 
family 
Have had genetic 
testing 
Aunts    
Uncles    
Grandmother    
Grandfather    
Male cousins    
Female cousins    
Half-sisters    
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Half-brothers    
 
Qualtrics 
Question type: Matrix Table > Constant Sum > Scale Point 
Validation: Max number = 100 
 
Second and Third-Degree Relatives 
 
30.  Please provide the number of relatives from your paternal (Father’s) 
side of the family for each of the categories 
 Total (living 
and 
deceased) 
Know about the 
mutation in the 
family 
Have had genetic 
testing 
Aunts    
Uncles    
Grandmother    
Grandfather    
Male cousins    
Female cousins    
Half-sisters    
Half-brothers    
 
Qualtrics 
Question type: Matrix Table > Constant Sum > Scale Point 
Validation: Max number = 100 
 
 
 
31.  Please provide the number of relatives from your family for each of the 
categories 
 
 Total (living 
and 
deceased) 
Know about the 
mutation in the 
family 
Have had genetic 
testing 
Nieces    
Nephews    
 
Qualtrics: 
Question type: Matrix Table>Constant Sum>Scale Point 
Question will display if number of brothers is >0 or if number of sisters is >0. 
Validation: Max number = 100 
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32.  Please provide the number of relatives from your family for each of the 
categories 
 Total (living 
and 
deceased) 
 Know about the 
mutation in the 
family 
Have had genetic 
testing 
Granddaughters    
Grandsons    
 
Qualtrics 
Question type: Matrix Table > Constant Sum > Scale Point 
Question will display if the number of sons is >0 or if the number of daughters is >0. 
Validation: Max number = 100 
 
 
Think about all of the second and third-degree relatives from the previous 
questions (aunts, uncles, grandparents, cousins, etc.). 
33. For female relatives who are alive and who have not had genetic testing, 
about what percentage are in the following categories? 
For reference: 0%= none, 50%=half, 100%=all 
 
Text box 
(number): 
 
 % - Do not plan to ever have genetic testing 
 % - Plan to have genetic testing, but not in the next 6 months 
 % - Plan to have genetic testing in the next 6 months 
 % - Plan to have genetic testing in the next month 
 
Qualtrics 
Question type: Constant Sum > Choices > Must Total 100% 
 
Think about all of the second and third-degree relatives from the previous 
questions (aunts, uncles, grandparents, cousins, etc.). 
34.  For male relatives who are alive and who have not had genetic testing, 
about what percentage are in the following categories? 
For reference: 0%= none, 50%=half, 100%=all 
 
Text box 
(number): 
 
 % - Do not plan to ever have genetic testing 
 % - Plan to have genetic testing, but not in the next 6 months 
 % - Plan to have genetic testing in the next 6 months 
 % - Plan to have genetic testing in the next month 
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Qualtrics 
Question type: Constant Sum > Choices > Must Total 100% 
 
 
 
Survey Page 7: Raffle entry 
If you would like to enter into the raffle for a chance to win a gift card, please provide your 
email address below. 
If you provide your email address, it will not be linked to your study responses, and only the 
study coordinator will have access to this email address.  The raffle is planned to occur 
during March 2019 – please check your email and spam filters around that time to see if you 
were selected.  After the raffle is complete, all emails will be deleted. 
Qualtrics 
Question type: Text Entry > Single line 
Have two entries with second to confirm address, and both must be valid email addresses. 
 
 
Survey Page 8: Final Page  
Thank you for your interest and participation in this survey.  The survey is now complete, 
and you may close the page. 
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